Redeye leaves a short comment following Cinclus’ announcement of having received positive CMC feedback from the EMA for linaprazan glurate. We view the aligned and supportive guidance from both EMA and FDA as an encouraging de-risking step in the regulatory process as Cinclus advances its ongoing phase III program.
LÄS MER
